INTRODUCTION AND OBJECTIVES:
For patients who develop castrate-resistant prostate cancer (CRPC), enzalutamide represents an androgen deprivation therapy (ADT) utilized by clinicians. However, as with other forms of ADT, patients become resistant to enzalutamide, prompting the need to identify agents with a novel mechanism of action. We identified exosomes derived from c-kit selected placental stem cells (PLSC) as a therapeutic option for CRPC.
METHODS: We isolated exosomes from conditioned media of PLSC by ultracentrifugation and characterized size distribution and number by nanoparticle tracking analysis, as well as protein and lipid content by Mass Spectrometry. We treated enzalutamide-sensitive(S) and resistant(R) C4-2B, CWR-R1, LNCaP cells, as well as non-neoplastic prostate (PREC-1 and PWR-R1) and fibroblast (M3T3) cells with PLSC exosomes. We tested the cytotoxicity of exosomes on all cell lines by MTT Assay. We then performed a clonogenic assay using the same dose of PLSC exosomes on C4-2B-S, C4-2B-R, and PWR-R1. Finally, to understand the mechanism behind their biological efficacy, we treated C4-2B cells with exosomes and examined changes in protein expression.
RESULTS: PLSC exosomes were loaded with high concentrations of saturated long chain fatty acids (LCFAs) (A). These exosomes inhibited cell viability of all prostate cancer cells lines by 30-50%. In addition, there was no effect on the viability of non-neoplastic cells. PLSC exosomes significantly inhibited clone formation in C4-2B-sensitive and resistant cells by 47% and 64%, respectively (B). There was no inhibition of clone formation in the non-neoplastic PWR-R1 cell line (C). Based on our protein and lipid data of PLSC exosomes, we explored the retinoic acid receptor pathway as a potential mechanism of action. We found that after treating C4-2B cells with exosomes, there was a significant increase in expression of retinoic acid receptor g.
CONCLUSIONS: PLSC exosomes selectively inhibit growth of enzalutamide-sensitive and resistant cell lines, without affecting the growth of non-cancerous cells. This growth inhibition is associated with an increase in retinoid acid receptor g, a known tumor suppressor that is regulated by LCFAs. We propose that the LCFAs loaded in exosomes activate retinoid acid receptor g, thus suppressing the growth of prostate cancer tumor cells.
Source of Funding: None

MP81-15 PROSTATE SMALL CELL CARCINOMA EXPRESS STEM CELL FACTORS THAT CAN TRANSFORM NORMAL AND CANCER CELLS INTO STEM-LIKE
Adelle Kanan, Alvin Liu*, Seattle, WA INTRODUCTION AND OBJECTIVES: Prostate cancer can be grouped into either luminal-like (differentiated) or stem-like (undifferentiated). The latter type includes small cell carcinoma. The LuCaP 145.1 small cell carcinoma xenograft line shows expression of stem cell transcription factors LIN28A, NANOG, POU5F1 and SOX2. Luminal-like adenocarcinoma LuCaP lines show expression of only one or two of these factors, while cancer cells of Gleason patterns 3 and 4 do not. Forced expression of these four genes in differentiated somatic cells produces induced pluripotent stem (iPS) cells. We want to determine if other LuCaP small cell carcinoma xenografts also express these genes, and whether these genes cloned from LuCaP 145.1 can also transform cell types, both normal and cancer, into stem-like.
METHODS: LuCaP small cell carcinoma harvested from mice were minced and digested by collagenase. The resultant cells were centrifuged on Percoll density gradients. Gene expression was analyzed by RT-PCR. Full-length LIN28A, NANOG, POU5F1 and SOX2 cDNA (Kozak box, ATG start to stop codon) were cloned from LuCaP 145.1 into mammalian expression vector pVITRO1-neo, and transfected by electroporation into HEK293F fibroblasts and luminal-like prostate cancer cells LNCaP and C4-2B. Individual colonies under drug G418 selection (1 mg/ml) were cloned, and analyzed for gene expression. Transfected cells were grown 1) in media supplemented with 10% fetal bovine serum under normoxia, 2) in serum-free media with KnockOut Serum Replacement, 3) on Matrigel-coated plates, 4) on irradiated mouse embryonic fibroblasts (MEF) under hypoxia.
RESULTS: The four stem cell factor genes were expressed by all established LuCaP small cell carcinoma examined: LuCaP 93, 145.1, 145.2, 173.1, 173.2A. LuCaP 145.1 cells also showed a stromal cell density (1.035). Transfection of plasmid pLP2 containing LIN28A/ POU5F1 and pSN4 containing SOX2/NANOG into HEK293F, LNCaP and C4-2 produced cells displaying a stem cell-like colony morphology. Neo (G418)-resistant cells appeared in~1 week, and showed expression of the stem cell factor genes as well as low expression of B2M (b 2-microglobulin) a characteristic of stem cells. The colony morphology was distinct from that of the untransfected cells, and showed differences among the culture conditions used.
CONCLUSIONS: Transcription factors cloned from small cell carcinoma are capable of transforming normal and cancer cells. The generated plasmid vectors are safer to use than lentiviral vectors; G418 allows selection of transfected cells, and deters microbial contamination.
Source of Funding: University of Washington CoMotion
MP81-16 MOLECULAR CHARACTERIZATION OF CANCER STEM CELLS FROM PROSTATE CANCER XENOGRAFTS
Sofia Karkampouna*, Maria De Menna, Markus Germann, Joel Grosjean, Bern, Switzerland; Peter Clark Gray, La Jolla, CA; George N. Thalmann, Marianna Kruithof-de Julio, Bern, Switzerland INTRODUCTION AND OBJECTIVES: Prostate cancer recurrence after androgen deprivation therapy is attributed to the existence of androgen-independent cancer stem cells, which differentiate into androgen-dependent cancer cells that reinitiate tumor growth. Phenotypic properties of cancer stem cell subpopulations versus highly proliferative progenitor cells remain to be further characterized in terms of androgen receptor signaling, quiescence/proliferation, tumorigenicity and therapy-resistance.
METHODS: To address the molecular basis of CSC switch from Androgen-dependency to independency we employed two patientderived xenograft models (LAPC-9, BM-18) that have different androgen sensitivity properties. We performed microarray and proteomic analysis of tumor tissues prior to/ following castration and after androgen replacement. Subpopulations are isolated based on combination of selected markers to assess their transcriptomic changes, in vitro and in vivo self-renewal.
RESULTS: Castration induces rapid tumor volume decrease of BM-18 and stabilization of tumor burden in the LAPC-9, reflecting different androgen dependent cell states. Proteomic analysis of bulk BM-18 tumors (intact, 14 days post castration, 50 days post Androgen e1102 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
